AzTrials
AzTrials

Osseointegration Failure of Dental ImplantNCT06453330

A Randomised Control Clinical Trial Investigating the Effect of H-PRF on Implant Stability and Marginal Bone Levels

A study testing Horizontal platelet-rich fibrin (H-PRF) in people with Osseointegration Failure of Dental Implant, run by University of Dublin, Trinity College at 1 site in Ireland.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record

Search all trials

Trial summary

This research will be a randomised controlled trial (RCT) investigating whether the use of Horizontal Platelet Rich Fibrin (H-PRF) increases implant stability compared to those implants placed without H-PRF, and therefore, contributes to the implant's overall success. Read more about this study

Who is it for?
Ages 18 years and olderHealthy volunteers can take part
What is being tested?
Horizontal platelet-rich fibrin (H-PRF)
Could I receive a placebo?
No, everyone receives an active treatment
How many people
27 participants
Where
1 siteIreland
Study dates
17 May 2024to 1 Jun 2026
Phase
Interventional

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • Patient Level
  • Male or Female, 18 years old or over
  • Capacity to provide informed consent
  • Willing to comply with study appointment schedule and willing to maintain a diary of symptoms
  • Planned for provision of dental implant(s) at Dublin Dental University Hospital Site Level
  • Sufficient bone volume for implant placement without the need for bone graft/augmentation; alveolar ridge of minimum 6mm width for standard implants (implant diameter 4mm) and of minimum 7mm for wider implants (implant diameter 5mm)

Who cannot join

  • Patient Level
  • Plaque score >20%
  • Bleeding score >20%
  • Tobacco smoking
  • Uncontrolled systemic disease
  • Use of systemic medications with an expected impact on bone healing (e.g. bisphosphonates)
Show all 10Show fewer
  • Pregnancy or lactation
  • Lack capacity to give informed consent
  • History of radiotherapy to the head and/or neck Site Level
  • Insufficient bone volume for implant placement, requiring bone graft/augmentation

Trial locations and contacts

1 site in 1 country.

Ireland1 site
  • Dublin Dental University Hospital

    Dublin, Dublin, D02 F859

Other trials in Ireland

About this study

Official title: A Randomised Control Clinical Trial Investigating the Effect of Horizontal-Platelet-Rich Fibrin (H-PRF) vs Standard Placement on Implant Stability and Marginal Bone Levels in Adults

This research will be a randomised controlled trial (RCT) investigating whether the use of Horizontal Platelet Rich Fibrin (H-PRF) increases implant stability compared to those implants placed without H-PRF, and therefore, contributes to the implant's overall success.

H-PRF is a second generation platelet concentrate that consists of a fibrin mesh containing cytokines and leukocytes. It has been shown to stimulate mesenchymal stem cells and osteoblasts that encourage bone formation as a result of the growth factors released from platelets, which should aid in osseointegration of implants. There is limited research that investigates the effects of H-PRF on implant stability. There is, however, some evidence that platelet-rich fibrin (PRF), which is produced in a fixed-angle centrifuge, increases implant stability and H-PRF is considered the evolution of PRF products.

Read more

This research would follow a H-PRF preparation protocol which involves taking a sample of venous blood from patients using a butterfly needle to collect up to 8-9ml tubes of blood. After the tube of blood is collected, it would immediately be placed in a horizontal centrifuge machine with 3 tubes of water to balance the centrifuge, and placed opposite each other. A set rpm and time will be chosen, and the centrifuge will run until the time is complete. The H-PRF clots would then be ready and taken out of the tubes to separate them from the red blood cells.

Following randomisation, implants will be placed in the upper or lower jaws of patients attending the Dublin Dental University Hospital using the standard implant protocol. Half of the implants will be coated with H-PRF, the other half (control group) would be placed without HPRF. Implant stability and marginal bone levels will be measured at three different stages: 1) Initial implant placement, 2) Second stage surgery when the implant is uncovered after healing and integrated with the bone, 3) When the definitive crown or bridge is attached to the implant. Insertion torque at baseline will also be measured. The above results will be collected and assessed to determine the effects of H-PRF, if any, on implant stability and the preservation of bone levels around implants.

Read the detailed description

This is a parallel arm, randomised control clinical Trial (RCT) on a cohort of Dublin Dental University Hospital patients who are having dental implants placed in the maxilla or mandible.

Study sample:

  1. Subjects will be recruited from a population of patients who have been referred to Dublin University Dental Hospital from general practice or specialist practice for provision of implants
  2. Subjects will be recruited from a population of patients who have been referred from another department within the Dublin Dental Hospital for provision of implants.

Enrolment and Consent:

Participants will be selected via two methods:

  1. Subjects will be recruited from a population of patients who have been referred to Dublin University Dental Hospital from general practice or specialist practice for provision of implants.
  2. Subjects will be recruited from a population of patients who have been referred from another department within the Dublin Dental University Hospital for provision of implants. Patients being referred for implants to the Dublin Dental University hospital initially attend a dental implant assessment appointment. If at that appointment they are deemed suitable to be enrolled in the study, a gatekeeper, Ms Niamh Leonard, will invite the patient to take part in the research study. (Please note that Ms Niamh Leonard is an experienced gatekeeper and an administrator in the Division of Restorative Dentistry and Periodontology in the Dublin Dental Hospital, but is not involved in study patient's care. She will only be involved in inviting patients to take part in the study). Patients will have an opportunity to discuss the study in detail and will be provided with a written copy of the Patient Information Leaflet (PIL) to take home. For any question that may arise regarding the research or the surgical procedure patients will be able to contact the co-investigator (Dr Rawan Kahatab) as the contact details appear on the information leaflet. Patients will be given time (at least 7 days) to consider their participation and can contact the gatekeeper if they opt to participate. Patients will sign a freely given informed consent form prior to their enrolment in the study.

If a single patient will be receiving more than one dental implants and there are numerous implant sites that qualify for entry into the research, only one of the implant sites will be randomly selected for the study. If a patient opts not to participate, it will not affect their care.

Randomisation:

At the time of surgery, each patient will select a numbered, sealed envelope with the treatment group allocation. Each envelope will correspond to a number on a computer-generated randomisation list created prior to enrolment of study participants. The operator will then use either the H-PRF or not use H-PRF when placing the implant depending on what was revealed when the envelope was opened. Neither the operator or the patient can be blinded to the arm chosen as blood sample will only be taken for the H-PRF group.

The blood sample collection and surgeries will be performed by Dr Rawan Kahatab.

H-PRF is used regularly in the DDUH and the clinical protocol will not deviate from standard procedures used at the hospital. H-PRF preparation protocol involves taking a sample of venous blood from patients using a butterfly needle to collect up to 8-9ml tubes of blood. After the first tube is collected, it would immediately be placed in a horizontal centrifuge machine, balanced out with 3 tubes of water, to ensure the centrifuge is properly balanced. A set rpm and time will be chosen, and the centrifuge will run until the time is complete. The H-PRF clots would then be ready and taken out of the tubes to separate them from the red blood cells. Peri-apical radiographs of the surgical site are taken pre-operatively, at implant placement and at implant restoration for all implants placed at the Dublin Dental University Hospital.

________________________________________________________________

Similar studies that have previously been carried out to assess the effect of PRF on implant stability have focused on PRF produced from fixed-angle systems as opposed to horizontal ones. However, they have followed a very similar design to our proposed design. For example, in a study by Tabrizi et al., (2017), a split-mouth randomised clinical trial was performed. Twenty patients with missing teeth in the molar region of the maxilla, requiring bilateral implants, were included. PRF was used on one side (group 1); no PRF was used on the other (group 2). Implant stability was assessed by resonance frequency analysis (RFA) at 2, 4, and 6 weeks after placement. At 2 weeks, the mean ISQ was 60.60 ± 3.42 in group 1 and 58.25 ± 3.64 in group 2; at 4 weeks it was 70.30 ± 3.36 in group 1 and 67.15 ± 4.33 in group 2; at 6 weeks it was 78.45 ± 3.36 in group 1 and 76.15 ± 2.94 in group 2. Significant differences in RFA were found between the groups at 2 weeks (P = 0.04), 4 weeks (P = 0.014), and 6 weeks (P = 0.027) after placement.

The study results suggest that the use of PRF may enhance the post-insertion stability of dental implants placed in the posterior maxilla during the healing period. In another study by Oncu et al., (2015), twenty healthy patients with adequate alveolar bone and two or more adjacent missing teeth extracted at least 6 months previously were included. A minimum of two tapered implants were placed in each patient. After surgical preparation of the implant sockets, PRF that had been prepared preoperatively was placed randomly into one of the sockets. Resonance frequency measurements were made after implant placement and at 1 week and 1 month postoperatively. Mean implant stability quotients (ISQs) of the PRF implants was 69.3 ± 10.5, and mean ISQs for the PRF- implants was 64.5 ± 12.2 at the end of the first week. The mean ISQs at 4 weeks postoperatively were 77.1 ± 7.1 for the PRF+ group and 70.5 ± 7.7 for the group without PRF. In this study, PRF application increased implant stability during the early healing period, as evidenced by higher ISQ values. Based on the results of these studies and the fact that H-PRF is an even more superior biomaterial than PRF, our study should achieve outcomes that are just as successful.

Being tested
Horizontal platelet-rich fibrin (H-PRF)

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Horizontal platelet-rich fibrin (H-PRF)Biological

    Most commercially available centrifuges used for PRF production are fixed-angle systems designed primarily for pelleting samples to the bottom of tubes and are not particularly efficient at separating the cell layers effectively. Research has demonstrated that PRF produced using horizontal centrifugation (H-PRF) can lead to a higher concentration of platelets and leukocytes compared to PRF produced from fixed-angle centrifugation (LPRF). The resulting PRF from horizontal centrifugation is termed 'horizontal platelet-rich fibrin' (H-PRF). The H-PRF clot will be produced using a Bio-PRF horizontal centrifuge machine. This machine is CE marked and regularly used in the Dublin Dental University Hospital.

Study groups in NCT06453330
Study groupRoleWhat they receive
An intervention group receiving standard placement of single implants with H-PRFExperimentalH-PRF preparation protocol involves taking a sample of venous blood from patients using a butterfly needle to collect up to 8-9ml tubes of blood. After the first tube is collected, it would immediately be placed in a horizontal centrifuge machine, balanced out with 3 tubes of water, to ensure the centrifuge is properly balanced. A set rpm and time will be chosen, and the centrifuge will run until the time is complete. The H-PRF clots would then be ready and taken out of the tubes to separate them from the red blood cells.
Receives: Biological: Horizontal platelet-rich fibrin (H-PRF)
A control group receiving standard placement of single implants without H-PRFNo interventionthis group will have standard implant placement without H-PRF

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Primary outcome: Implant Stability Quotient (ISQ) using magnetic resonance frequency analysis (MRFA)

    This is a measurement of the stability of the implant

    Measured: At implant placement, at 3 months and at 4-5 months (implant restoration)

Secondary outcomes (3)
  1. Secondary outcomes: Marginal bone levels

    The level of bone around the implant

    Measured: At implant placement, at 3 months and at 4-5 months (implant restoration)

  2. Rate of pain experienced based on a visual analog scale 1-10

    Rate of pain experienced using a survey that will be given to patients. They will be given a visual analog scale and asked to use that to rate their pain.

    Measured: after local anaesthetic wears away, 24 hours after implant placement and 1 week after implant placement

  3. Number of participants with implant loss/fracture/infection

    Any implant failures/infections. This includes loss of implant, fracture of the implant or infection of the implant site.

    Measured: At any point from implant placement until 4-5 months afterwards

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted11 Jun 2024
  2. Study start17 May 2024
  3. Primary completion1 Jun 2026
  4. Study completion1 Jun 2026

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Other
Allocation
Randomised
Intervention model
Parallel groups
Model description
An intervention group receiving standard placement of single implants with H-PRF and a control group receiving standard placement of single implants without H-PRF
Masking
None (open label)
Enrolment
27 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06453330
Sponsor's protocol ID
3470
Status last verified
Apr 2026
First submitted
5 Jun 2024
Last updated
20 Oct 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No: It is unlikely that patient data (Identification and personal details) will be shared, only the outcome measurements and details of where the implant was placed.

Publications

  • Tabrizi R, Arabion H, Karagah T. Does platelet-rich fibrin increase the stability of implants in the posterior of the maxilla? A split-mouth randomized clinical trial. Int J Oral Maxillofac Surg. 2018 May;47(5):672-675. doi: 10.1016/j.ijom.2017.07.025. Epub 2017 Dec 18.

    PubMed 29269149
  • Oncu E, Alaaddinoglu EE. The effect of platelet-rich fibrin on implant stability. Int J Oral Maxillofac Implants. 2015 May-Jun;30(3):578-82. doi: 10.11607/jomi.3897.

    PubMed 26009908
  • Miron RJ, Chai J, Zheng S, Feng M, Sculean A, Zhang Y. A novel method for evaluating and quantifying cell types in platelet rich fibrin and an introduction to horizontal centrifugation. J Biomed Mater Res A. 2019 Oct;107(10):2257-2271. doi: 10.1002/jbm.a.36734. Epub 2019 Jun 12.

    PubMed 31148358
  • Lucarelli E, Beccheroni A, Donati D, Sangiorgi L, Cenacchi A, Del Vento AM, Meotti C, Bertoja AZ, Giardino R, Fornasari PM, Mercuri M, Picci P. Platelet-derived growth factors enhance proliferation of human stromal stem cells. Biomaterials. 2003 Aug;24(18):3095-100. doi: 10.1016/s0142-9612(03)00114-5.

    PubMed 12895582
  • Uggeri J, Belletti S, Guizzardi S, Poli T, Cantarelli S, Scandroglio R, Gatti R. Dose-dependent effects of platelet gel releasate on activities of human osteoblasts. J Periodontol. 2007 Oct;78(10):1985-91. doi: 10.1902/jop.2007.070116.

    PubMed 18062120
  • Anitua EA. Enhancement of osseointegration by generating a dynamic implant surface. J Oral Implantol. 2006;32(2):72-6. doi: 10.1563/736.1.

    PubMed 16704108
  • Fujioka-Kobayashi M, Kono M, Katagiri H, Schaller B, Zhang Y, Sculean A, Miron RJ. Histological comparison of Platelet rich fibrin clots prepared by fixed-angle versus horizontal centrifugation. Platelets. 2021 Apr 3;32(3):413-419. doi: 10.1080/09537104.2020.1754382. Epub 2020 Apr 18.

    PubMed 32306811

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in